Top

Published in:

01-01-2017 | Original Article

Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus

Authors: Toshiyasu Ojima, Mikihito Nakamori, Masaki Nakamura, Masahiro Katsuda, Keiji Hayata, Yasushi Nakamura, Hiroki Yamaue

Published in: Surgery Today | Issue 1/2017

Abstract

Purpose

The aim of this study was to identify the biomarkers associated with chemotherapeutic efficacy and long-term survival for patients with advanced squamous cell carcinoma of the esophagus (SCCE) who had received neoadjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil (NAC-DCF).

Methods

This study included 45 patients with advanced SCCE who received NAC-DCF between 2008 and 2012. The NAC-DCF was conducted as a phase II study (UMIN000007408). The expressions of excision repair cross-complementing-1 (ERCC1), class III beta-tubulin, breast cancer susceptibility gene I (BRCA1), and thymidylate synthase were investigated simultaneously in the pre-treatment endoscopic tumor biopsy samples.

Results

A multivariate logistic regression analysis indicated that pathological responses were significantly associated with tumors with low ERCC1 expression (P = 0.016) and with tumors with high BRCA1 expression (P = 0.030). The multivariate Cox proportional hazard model analysis for relapse-free survival revealed high BRCA1 expression (P = 0.031, hazards ratio 4.39) as the factor associated with survival.

Conclusions

Low ERCC1 expression and high BRCA1 expression in patients with SCCE were associative biomarkers for chemotherapeutic efficacy. High BRCA1 expression was considered the factor associated with survival. These findings may be helpful for tailoring chemotherapy.

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with CDDP and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74. doi:10.1245/s10434-011-2049-9.CrossRefPubMed

Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, et al. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol. 2014;21:2838–44. doi:10.1245/s10434-014-3684-8.CrossRefPubMed

Ui T, Fujii H, Hosoya Y, Nagase M, Mieno MN, Mori M, et al. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus. Dis Esophagus. 2015;28:180–7. doi:10.1111/dote.12187.CrossRefPubMed

Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1455–60. doi:10.1111/cas.12274.CrossRefPubMed

Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, et al. Neoadjuvant chemotherapy with divided-dose docetaxel, cisplatin and fluorouracil for patients with squamous cell carcinoma of the esophagus. Anticancer Res. 2016;36:829–34.PubMed

Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254–9. doi:10.1200/JCO.2008.18.8631.CrossRefPubMed

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11:2215–21.CrossRefPubMed

Warnecke-Eberz U, Vallböhmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E, et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg. 2009;13:1411–21. doi:10.1007/s11605-009-0881-z.CrossRefPubMed

Langer R, Specht K, Becker K, Ewald P, Bekesch M, Sarbia M, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res. 2005;11:7462–9.CrossRefPubMed

10.

Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, et al. High specificity of quantitative excision repair cross-complementing-1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004;10:3794–9.CrossRefPubMed

11.

Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, et al. Excision-repair cross-complementing-1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Mol Med Rep. 2009;2:903–9. doi:10.3892/mmr_00000190.CrossRefPubMed

12.

Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 2013;14:558–67. doi:10.1016/j.cllc.2013.04.013.CrossRefPubMed

13.

Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C. Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med. 2011;11:726–31.CrossRefPubMed

14.

Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, Pelletier LB, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol. 2011;22:2403–10. doi:10.1093/annonc/mdq770.CrossRefPubMed

15.

Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9. doi:10.1200/JCO.2008.20.7019.CrossRefPubMed

16.

Weberpals J, Garbuio K, O’Brien A, Clark-Knowles K, Doucette S, Antoniouk O, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer. 2009;124:806–15. doi:10.1002/ijc.23987.CrossRefPubMed

17.

Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, et al. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One. 2013;8:e52589. doi:10.1371/journal.pone.0052589.CrossRefPubMedPubMedCentral

18.

Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D’Amico TA, Sporn T, et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001;7:562–9.PubMed

19.

Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang L, et al. Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: a hierarchical clustering analysis. Exp Ther Med. 2014;7:1578–82.PubMedPubMedCentral

20.

Sobin LH, Wittekind CH. International Union Against Cancer (UICC): TNM classification of malignant tumors. UICC Cancer Staging Manual. 6th ed. New York: Wiley; 2002.

21.

Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Matsumura S, et al. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. Dis Esophagus. 2016;. doi:10.1111/dote.12450 (epub ahead of print).PubMed

22.

Ojima T, Iwahashi M, Nakamori M, Nakamura M, Katsuda M, Iida T, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2014;44:839–47. doi:10.1007/s00595-013-0616-3.CrossRefPubMed

23.

Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.CrossRef

24.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.CrossRefPubMed

25.

Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol. 2003;163:957–67.CrossRefPubMedPubMedCentral

26.

Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol. 1999;155:2057–66.CrossRefPubMedPubMedCentral

27.

Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74:777–86. doi:10.1007/s00280-014-2562-1.CrossRefPubMed

28.

Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54:3500–5.PubMed

29.

Sun JM, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;80:655–60. doi:10.1016/j.ijrobp.2010.02.061.CrossRefPubMed

30.

Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54–60.CrossRefPubMed

31.

Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504–9.CrossRefPubMed

32.

Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet. 2002;360:1007–14.CrossRefPubMed

33.

Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 2011;103:1552–6. doi:10.1093/jnci/djr326.CrossRefPubMed

34.

Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999;97:575–86.CrossRefPubMed

35.

Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 2001;20:6597–606.CrossRefPubMed

36.

Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, et al. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today. 2016;46:261–7. doi:10.1007/s00595-015-1144-0.CrossRefPubMed

37.

Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M, et al. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients. Surg Today. 2016;46:405–13. doi:10.1007/s00595-015-1197-0.CrossRefPubMed

Title: Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus
Authors: Toshiyasu Ojima
Mikihito Nakamori
Masaki Nakamura
Masahiro Katsuda
Keiji Hayata
Yasushi Nakamura
Hiroki Yamaue
Publication date: 01-01-2017
Publisher: Springer Japan
Published in: Surgery Today / Issue 1/2017
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-016-1338-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Outcomes of lung cancer surgery in patients with coronary artery disease: a decade of experience at a single institution

Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry

Clinicopathological characteristics of cancer associated with Crohn’s disease

Impact of sarcopenia on surgical site infection after restorative proctocolectomy for ulcerative colitis

Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy

Cell sheet technology for the regeneration of gastrointestinal tissue using a novel gastric perforation rat model